Advertisement
Home »

Combining PARP Inhibition & Androgen Receptor-Signaling Inhibition Improves Survival in HRR-Deficient mCRPC

Jun 08, 2023

REFERENCES & ADDITIONAL READING

Agarwal N, et al. The Lancet. Published online ahead of print: June 4, 2023. doi:10.1016/S0140-6736(23)01055-3

De Bono JS, et al. Lancet Oncol. 2021;22:1250-1264.

Fizazi K, et al. TALAPRO-2: phase 3 study of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations (HRR-deficient population). Abstract 5004. ASCO Annual Meeting 2023, 2–6 June, Chicago.

 

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement